Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.67 |
| ▸ | CA2 | P00918 | 12/20 | 0.67 |
| ▸ | CA9 | Q16790 | 12/20 | 0.67 |
| ▸ | CA12 | O43570 | 6/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.65 |
| ▸ | CA7 | P43166 | 1/20 | 0.65 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | HTR3A | P46098 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24444501 | 0.91 | CA9 (0.72) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13815114 | 0.90 | CA1 (0.71) | CA1CA2CA9CA12CA14 | |
| SCHEMBL12678101 | 0.89 | CA9 (0.72) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13219607 | 0.89 | CA1 (0.72) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13915130 | 0.88 | CA9 (0.73) | CA1CA2CA9CA12CA14 | |
| SCHEMBL19426705 | 0.88 | CA9 (0.71) | CA1CA2CA9CA12CA14 | |
| SCHEMBL24817798 | 0.88 | CA1 (0.65) | CA1CA2CA9CA12CA14 | |
| SCHEMBL14642801 | 0.87 | CA1 (0.67) | CA1CA2CA9CA12CA14 | |
| SCHEMBL12185092 | 0.87 | CA9 (0.73) | CA1CA2CA9CA12CA14 | |
| SCHEMBL1638181 | 0.86 | CA1 (0.75) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263886-A1 | VACCINES, VACCINE PRIMING, AND ANTIGEN DOSE SPARING | ADJUVANCE TECHNOLOGIES, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230128815-A1 | ADJUVANT COMPOUNDS, SALT FORMS, AND FORMULATIONS | ADJUVANCE TECH INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20210299237-A1 | TRITERPENE SAPONIN SYNTHESIS, INTERMEDIATES AND ADJUVANT COMBINATIONS | ADJUVANCE TECHNOLOGIES, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210283248-A1 | TRITERPENE SAPONIN ANALOGUES | ADJUVANCE TECHNOLOGIES, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| US-20200164065-A1 | TRITERPENE SAPONIN ANALOGUES | ADJUVANCE TECHNOLOGIES, INC. (US) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299237-A1 | TRITERPENE SAPONIN SYNTHESIS, INTERMEDIATES AND ADJUVANT COMBINATIONS | SQLE, LSS, MYD88 | CA1 2866/4885CA2 3185/4885CA9 3528/4885 |
| US-20230128815-A1 | ADJUVANT COMPOUNDS, SALT FORMS, AND FORMULATIONS | MYD88, TLR7, NFATC1 | CA1 1273/4885CA2 484/4885CA9 1513/4885 |
| US-20210283248-A1 | TRITERPENE SAPONIN ANALOGUES | LSS, NFATC1, PGGT1B | CA1 2984/4885CA2 2862/4885CA9 3154/4885 |
| US-20200164065-A1 | TRITERPENE SAPONIN ANALOGUES | LSS, NFATC1, PGGT1B | CA1 2984/4885CA2 2862/4885CA9 3154/4885 |
| US-20230263886-A1 | VACCINES, VACCINE PRIMING, AND ANTIGEN DOSE SPARING | MYD88, CD14, DDOST | CA1 1363/4885CA2 1525/4885CA9 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.